Advertisement

The Threat from Viruses

  • Patrick L. Iversen
Chapter

Abstract

Infectious disease represent the most significant threat to human health. Significant geologic cataclysmic events have caused the extinction of countless species, but these “Wrath of God” events predate the emergence of Homo sapiens. Pandemic infections have accompanied the rise of human civilization frequently re-occurring leaving a lasting imprint on human history punctuated by profound loss of life. Emerging infections become endemic and are here to stay marking their presence with an annual death toll. Each decade brings a new onslaught of emerging infectious agents. We are surprised again and again but are never prepared. The long-term consequences often remain unrecognized and are always inconvenient including cancer, cardiovascular disease and immune associated diseases that threaten our health. Reliance on clusters of clinical symptoms in the face of diverse and non-descriptive viral infection symptoms is a foolhardy form of crisis management. Viral success is based on rapid replication resulting in large numbers. Single-stranded RNA viruses with their high replication error rate represent a paradigm for resilience.

Keywords

Emerging infectious disease Endemic Outbreak Pandemic Epidemic Zoonotic Epidemiologic 

References

  1. Agrawal S. Antisense oligonucleotide-based therapy for HIV-1 infection from laboratory to clinical trials. In: Wickstrom E, editor. Clinical trials of genetic therapy with antisense DNA and DNA vectors. New York: Marcel Dekker; 1998. p. 331–52.Google Scholar
  2. Agrawal S, Goodchild J, Civer MP, Thornton AH, Sarin PS, Zamecnik PC. Oligodeoxynucleotide phosphoramidates and phosphorothioates as inhibitors of human immunodeficiency virus. Proc Natl Acad Sci U S A. 1988;85:7079–83.CrossRefGoogle Scholar
  3. Bausch DG, Bangura J, Garry RF, Goba A, Grant DS, Jacquerioz FA, McLellan SL, Jalloh S, Moses LM, Schieffelin JS. A tribute to Sheik Humarr Khan and all the healthcare workers in West Africa who have sacrificed in the fight against Ebola virus disease: mae we hush. Antivir Res. 2014;111:33–5.CrossRefGoogle Scholar
  4. Bok K, Cavanaugh VJ, Matson DO, Gonzalez-Molleda L, Chang KO, Zintz C, Smith AW, Iversen PL, Green KY, Campbell. Inhibition of Norovirus replication by Morpholino oligomers targeting the 5’-end of the genome. Virology. 2008;380(2):328–37.CrossRefGoogle Scholar
  5. Breitbart M. Marine viruses: truth or dare. Ann Rev Mar Sci. 2012;4:425–48.CrossRefGoogle Scholar
  6. Burkitt’s lymphoma (Crawford DH, Rickinson A, Johannessen I). Cancer virus. New York: Oxford University Press; 2014.Google Scholar
  7. Centers for Disease Control and Prevention. Oseltamivir-resistant 2009 pandemic influenza A (H1N1) virus infection in two summer campers receiving prophylaxis—North Carolina. MMWR Morb Mortal Wkly Rep. 2009;58:969–72.Google Scholar
  8. De Clercq E, Li G. Approved antiviral drugs of the past 50 years. Clin Microbiol Rev. 2016;29(3):695–747.CrossRefGoogle Scholar
  9. De Cock KM. The Eradicatio of smallpox: Edward Jenner and the first and only eradication of a human infectious disease. Nat Med. 2001). (book review);7(1):15–6.CrossRefGoogle Scholar
  10. de Jong MD, Thanh TT, Khanh TH, Hien VM, Smith GJD, Chau NG, Cam BV, Qui PT, Ha DQ, Guan Y, Malik Peiris JS, Hien TT, Farrar J. Oseltamivir resistance during treatment of influenza A (H5N1) infection. N Engl J Med. 2005;353:2667–72.CrossRefGoogle Scholar
  11. Deas TS, Bennett CJ, Jones SA, Tilgner M, Ren P, Behr MJ, Stein DA, Iversen PL, Kramer LD, Bernard KA, Shi P-Y. In vitro resistance and in vivo efficacy of antisense oligomer against West Nile virus. Antimicrob Agents Chemother. 2007;51(7):2470–82.CrossRefGoogle Scholar
  12. Dharan NJ, Patton M, Siston AM, Morita J, Ramierez E, Wallis TR, Deyde V, Gubareva LV, Klimov AI, Bresee JS, Fry AM. Outbreak of antiviral drug-resistant influenza A in long-term care facility, Illinois, USA. Emerg Infect Dis. 2008. [Serial on the internet] 2009. http://wwwnc.cdc.gov/eid/article/15/12/08-1644.
  13. Fauci AS, Morens DM. The perpetual challenge of infectious disease. New Engl J Med. 2012;366:454–61.CrossRefGoogle Scholar
  14. Feng H, Shuda M, Chang Y, Moore P. Clonal integration of a polyomavirus in human Merkel cell carcinoma. Science. 2008;319:1096–100.CrossRefGoogle Scholar
  15. Gabriel G, Nordman A, Stein DA, Iversen PL, Klend H-D. Morpholino oligomers targeting the PB1 and NP genes enhance survival of mice infected with highly pathogenic influenza A H7N7 virus. J Gen Virol. 2008;89:939–48.CrossRefGoogle Scholar
  16. Ge Q, Pastey M, Kobasa D, Puthavathana P, Lupfer C, Bestwick RK, Iversen PL, Chen J, Stein DA. Inhibition of multiple subtypes of influenza a virus in cell cultures with morpholino oligomers. Antimicrob Agents Chemother. 2006;50(11):3724–33.CrossRefGoogle Scholar
  17. Heald AE, Iversen PL, Saoid JB, Sazani P, Charleston JS, Axtelle T, Wong M, Smith WB, Vutikullird A, Kaye E. Safety and pharmacokinetic profiles of phosphorodiamidate morpholino oligomers with activity against Ebola virus and Marburg virus: results of two single ascending dose studies. Antimicrob Agents Chemother. 2014;58(11):6639–47. PMID 25155593CrossRefGoogle Scholar
  18. Hebar H, et al. Cytomegalovirus infection and atherosclerosis in candidate of coronary artery bypass graft. Microbiol. 2015;8(3):e15476.Google Scholar
  19. Holden KL, Stein DA, Pierson TC, Ahmed AA, Clyde K, Iversen PL, Harris E. Inhibition of dengue virus translation and RNA synthesis by a morpholino oligomer targeted to the terminal 3′ stem-loop structure. Virology. 2006;344:439–52.CrossRefGoogle Scholar
  20. Iversen PL, Mata JE, Tracewell WG, Zon G. Pharmacokinetics of an antisense phosphorothioate oligodeoxynucleotide against rev from human immunodeficiency virus type 1 in the adult male rat following single injections and continuous infusion. Antisense Res Dev. 1994;4:43–52.CrossRefGoogle Scholar
  21. Jacobson JM, Lalezari JP, Thommpson MA, Fichtenbaum CJ, Saag MS, Zingman BS, D’Ambrosio P, Stambler N, Rotshteyn Y, Marozsan AJ, Maddon PJ, Morris SA, Olson WC. Phase 2a study of the CCR5 monoclonal antibody PRO 140 administered intravenously to HIV-infected adults. Antimicrob Agents Chemother. 2010a;54:4137–42.CrossRefGoogle Scholar
  22. Jacobson JM, Thompson MA, Lalezari JP, Saag MS, Zingman BS, PD’Ambrosio, Stambler N, Rotshteyn Y, Marozsan AJ, Maddon PJ, Morris SA, Olson WC. Anti-HIV-1 activity of weekly or biweekly treatment with subcutaneous PRO 140, a CCR5 monoclonal antibody. J Infect Dis. 2010b;201:1481–7.CrossRefGoogle Scholar
  23. Jefferson T, Jones M, Doshi P, Spencer EA, Onakpoya I, Heneghan CJ. Oseltamivir for influenza in adults and children: systemic review of clinical study reports and summary of regulatory comments. Br Med J. 2014;348:2545–63.CrossRefGoogle Scholar
  24. Keller MA, Stiehm ER. Passive immunity in prevention and treatment of infectious diseases. Clin Microbiol Rev. 2000;13:602–14.CrossRefGoogle Scholar
  25. Khiabanian H, Carpenter Z, Kugelman J, Chan J, Trifonov V, Nagle E, Warren T, Iversen P, Bavari S, Palacios G, Rabadan R. Viral diversity and clonal evolution from unphased genomic data. BMC Genomics. 2014;15(suppl 6):S17. PMID 25573168CrossRefGoogle Scholar
  26. Kimura M, Jia ZJ, Nakayama N, Asakawa S. Ecology of viruses in soils: past, present and future perspectives. Soil Sci Plant Nutr. 2008;54:1–32.CrossRefGoogle Scholar
  27. Kinney RM, Huang CL-H, Rose BC, Kroeker AD, Dreher TW, Iversen PL, Stein DA. Inhibition of dengue virus serotypes 1 to 4 in cell culture with Morpholino oligomers. J Virol. 2005;79(8):5116–28.CrossRefGoogle Scholar
  28. Lai SH, Stein DA, Liao SL, Guerrero-Plata A, Hong C, Iversen PL, Casola A, Garofalo RP. Inhibition of respiratory Syncitial virus infections in cell cultures and in mice with morpholino oligomers. Mol Ther. 2008;16(6):1120–8.CrossRefGoogle Scholar
  29. Lam TTY, Zhou B, Wang J, Chai Y, Shen Y, Chen X, Ma C, Hong W, Chen Y, Zhang Y, Duan L, Chen P, Jiang J, Zhang Y, Li L, Poon LLM, Webby RJ, Smith DK, Leung GM, Malik Peiris JS, Holmes ED, Guan Y, Zhu H. Dissemination, divergence and establishment of H7N9 influenza viruses in China. Nature. 2015;552:102–5.CrossRefGoogle Scholar
  30. Lee K. Health impact of globalization: towards global governance. New York: Palgrave Macmillan; 2003. p. 131.CrossRefGoogle Scholar
  31. Lupfer C, Stein DA, Mourich DV, Tepper SE, Iversen PL, Pastey M. Inhibition of influenza A H3N8 virus infections in mice by morpholino oligomers. Arch Virol. 2008;153:929–37.CrossRefGoogle Scholar
  32. Martin-Alonso JM, Skilling DE, Gonzalex-Molleda L, del Barrio G, Machin A, Keefer NK, Matson DO, Iversen PL, Smith AW, Parra F. Isolation and characterization of a new Vesivirus from rabbits. Virology. 2005;337:373–83.CrossRefGoogle Scholar
  33. Matsukura M, Shinozuka K, Zon G, Mitsuya H, Reitz M, Cohen JS, Broder S. Phosphorothioate analogs of oligodeoxyribonucleotides: inhibitors of replication and cytopathic effects of human immunodeficiency virus. Proc Natl Acad Sci U S A. 1987;84:7706–10.CrossRefGoogle Scholar
  34. Meyer TJ, Rosenkrantz JL, Carbone L, Chavez SL. Endogenous retroviruses: with us and against us. Front Chem. 2017;5:23.CrossRefGoogle Scholar
  35. Michiels B, Van Puyenbroeck K, Verhoeven V, Vermeire E, Coenen S. The value of neuraminidase inhibitors for the prevention and treatment of seasonal influenza: a systematic review of systematic reviews. PLoS One. 2013;8:e60348.  https://doi.org/10.1371/journal.pone.0060348.CrossRefPubMedPubMedCentralGoogle Scholar
  36. Morales-Sanchez A, Fuentes-Panana E. Human viruses and cancer. Viruses. 2014;6:4047–79.CrossRefGoogle Scholar
  37. Neuman BW, Stein DA, Kroeker AD, Paulino AD, Moulton HM, Iversen PL, Buchmeier MJ. Antisense morpholino oligomers directed against the 5’-end of the genome inhibit coronavirus proliferation and growth. J Virol. 2004;78(11):5891–9.CrossRefGoogle Scholar
  38. Neuman BW, Stein DA, Kroeker AD, Churchill MJ, Kim AM, Dawson P, Moulton HM, Bestwick RK, Iversen PL, Buchmeier MJ. Inhibition, escape and attenuation of SARS coronavirus treated with antisense morpholino oligomers. J Virol. 2005;79:9665–76.CrossRefGoogle Scholar
  39. Nichols KE, et al. Inactivating mutations in an SH2 domain-encoding gene in X-linked lymphoproliferative syndrome. PNAS. 1998;95:13765–70.CrossRefGoogle Scholar
  40. Paessler S, Rijnbrand R, Stein DA, Ni H, Yun NE, Dziuba N, Borisevich V, Seregin A, Ma Y, Blouch R, Iversen PL, Zacks MA. Inhibition of alphavirus infection in cell culture and in mice with antisense morpholino oliogmers. Virology. 2008;5(2):357–70.CrossRefGoogle Scholar
  41. Purtilo D, et al. Immunological disorders and malignancies in five young brothers. Arch Dis Child. 1977;52(4):310–3.CrossRefGoogle Scholar
  42. Quammen D. Spillover animal infections and the next human pandemic. New York: WW Norton & Co; 2012. p. 493–520.Google Scholar
  43. Reche I, D’Orta G, Mladenov N, Winget DM, Suttle CA. Deposition rates of viruses and bacteria above the atmospheric boundary layer. ISME J. 2018;12:1154–62.PubMedGoogle Scholar
  44. Roa PL, et al. A prospective monitoring study of cytomegalovirus infection in non-immunosuppressed critical heart surgery patients. PLoS One. 2015;10(6):e0129447.CrossRefGoogle Scholar
  45. Sarin PS, Agrawal S, Civeira MP, Goodchild J, Ikeuchi T, Zamecnik PC. Inhibition of acquired immunodeficiency syndrome virus by oligonucleotide methylphosphonates. Proc Natl Acad Sci U S A. 1988;85:7448–51.CrossRefGoogle Scholar
  46. Schnell FJ, Sundholm S, Crumley S, Iversen PL, Mourich DV. Lymphocytic Choriomeningitis virus infection in FVB mouse produces hemorrhagic disease. PLoS Pathog. 2012;8(12):e1003073.CrossRefGoogle Scholar
  47. Scientific American. Ancient Athenian plague proves to be typhoid. 2006, January 25.Google Scholar
  48. Sleeman K, Stein DA, Tamin A, Reddish M, Iversen PL, Rota PA. Inhibition of Measles virus infection in cell cultures by peptide-conjugated Morpholino oligomers. Virus Res. 2009;140:49–56.CrossRefGoogle Scholar
  49. Smith AW, Iversen PL, Skilling DE, Stein DA, Bok K, Matson DO. Vesivirus viremia and Seroprevalence in humans. J Med Virol. 2006;78:693–701.CrossRefGoogle Scholar
  50. Smith AW, Iversen PL, O’Hanley P, Christensen JR, Stein DA, Skilling DE, Weaver SS, Longley K, Stone M, Poet SE, Matson DO. Virus specific antiviral therapy for controlling severe and fatal outbreaks of feline Calicivirus infection. Am J Vet Res. 2008;69(1):23–32.CrossRefGoogle Scholar
  51. Stanley DA, et al. Chimpanzee adenovirus vaccine generates acute and durable protective immunity against ebolavirus challenge. Nat Med. 2014;20:1126–9.CrossRefGoogle Scholar
  52. Stein DA, Skilling DE, Iversen PL, Smith AW. Inhibition of Vesivirus infetions in mammalian tissue culture with antisense morpholino oligomers. Antisense Nucleic Acid Drug Dev. 2001;11:317–25.CrossRefGoogle Scholar
  53. Stephenson ML, Zamecnik PC. Inhibition of Rous sarcoma viral RNA translation by a specific oligodeoxynucleotide. Proc Natl Acad Sci U S A. 1978;75:285–8.CrossRefGoogle Scholar
  54. Stone J, Stein DA, Rijnbrand R, Iversen PL, Andino R. Inhibition of multiple species of picornavirus using a morpholino oligomer targeting highly conserved IRES sequence. Antimicrob Agents Chemother. 2008;52(6):1970–81.CrossRefGoogle Scholar
  55. Sun Z, Lu P, Gail MH, et al. Increased risk of hepatocellular carcinoma in male hepatiis B surface antigen carriers with chronic hepatitis who have detectable aflatoxin metabolite M1. Hepatology. 1999;20:379–83.CrossRefGoogle Scholar
  56. Suttle CA. Viruses in the sea. Nature. 2005;437:356–61.CrossRefGoogle Scholar
  57. Swenson DL, Warfield KL, Warren TK, Moulton H, Blouch R, Ruthel G, Iversen PL, Bavari S. Chemical modifications to phosphorodiamidate Morpholino oligomer antisense molecules targeting VP24 modify their efficacy against Ebola virus infection. Antimicrob Agents Chemother. 2009;53(5):2089–99.CrossRefGoogle Scholar
  58. Tapia MD, et al. Use of ChAd3-EBO-Z Ebola virus vaccine in Malian adults with MVA-BN-Filo: a phase I, single-blind, randomized trial, a phase 1b, open label and double blind, dose-escallation trial, and a nested, randomized, double-blind, placebo-controlled trial. Lancet Infect Dis. 2016;16:31–42.CrossRefGoogle Scholar
  59. Vagnozzi A, Stein DA, Iversen PL, Rieder E. Inhibition of foot-and-mouth disease virus in cell cultures with antisense morpholino oligomers. J Virol. 2007;81(21):11669–80.CrossRefGoogle Scholar
  60. van den Born E, Stein DA, Iversen PL, Snijder EJ. Antiviral activity of morpholino oligomers designed to block various aspects of Equine arteritis virus amplification in cell culture. J Gen Virol. 2005;86(11):3081–90.CrossRefGoogle Scholar
  61. Wang W, Song Z, Guan W, Liu Y, Zhang X, Xu L, Li J, Yuan Z, Hu Y. PCR for detection of oseltamivir resistance mutation in influenza A(H7N9) virus. Emerg Infect Dis. 2014;20:847–9.CrossRefGoogle Scholar
  62. Wang TT, et al. IgG antibodies to dengue enhanced for FcγRIIIA binding determine disease severity. Science. 2017;355:395–8.CrossRefGoogle Scholar
  63. Warfield KL, Swenson DL, Olinger GG, Nichols DK, Pratt WD, Blouch R, Stein DA, Aman MJ, Iversen PL, Bavari S. Gene-specific countermeasures against Ebola virus based on antisense phosphorodiamidate morpholino oligomers. PLoS Pathog. 2006;2(1):1–9.CrossRefGoogle Scholar
  64. Warren TK, Warfield KL, Wells J, Swenson DL, Donner KS, Van Tongeren SA, Garza NL, Dong L, Mourich DV, Crumley S, Nichols DK, Iversen PL, Bavari S. Advanced antisense therapies for postexposure protection against lethal filovirus infections. Nat Med. 2010;16:991–4.CrossRefGoogle Scholar
  65. Warren TK, Witehouse CA, Iversen PL, Bavari S. Single component AVI-7537 antisense compound provides greater protection than double component AVI-6002 against Lethal Ebola virus infection in Rhesus Monkeys. MBio. 2015;6(1):e02344-14. PMID 25670780CrossRefGoogle Scholar
  66. Wulff H, McIntosh B, Hamner D, Johnson K. Isolation of an arenavirus closely related to Lassa virus from Mastomys natalensis in south-east. Africa Bull World Health Organ. 1977;55:441–4.PubMedGoogle Scholar
  67. Yuan J, Stein DA, Lim T, Qiu D, Coughlin S, Liu Z, Wang Y, Blouch R, Moulton HM, Iversen PL, Yang D. Inhibition of coxsackievirus b3 in cell cultures and in mice by Peptide-conjugated morpholino oligomers targeting the internal ribosomal entry site. J Virol. 2006;80(23):11510–9.CrossRefGoogle Scholar
  68. Zamecnik PC, Stephenson ML. Inhibition of Rous sarcoma virus replication and transformation by a specific oligodeoxynucleotide. Proc Natl Acad Sci U S A. 1978;75:280–4.CrossRefGoogle Scholar
  69. Zech L, et al. Characteristic chromosomal abnormalities in biopsies and lymphoid-cell lines from patients with Burkitt and non-Burkitt lymphomas. Int J Cancer. 1976;17:47–56.CrossRefGoogle Scholar
  70. Zhang W, et al. Effect of early and late GB virus C viremia on survival of HIV-infected individuals: a meta-analysis. HIV Med. 2006a;7:173–80.CrossRefGoogle Scholar
  71. Zhang YJ, Stein DA, Fan SM, Wang KY, Kroeker AD, Meng XJ, Iversen PL, Matson DO. Suppression of porcine reproductive and respiratory syndrome virus replication by morpholino antisense oligomers. Vet Microbiol. 2006b;117(2–4):117–29.CrossRefGoogle Scholar
  72. Zhang B, Dong H, Stein DA, Iversen PL, Shi PY. West Nile virus genome cyclization and RNA replication require two pairs of long-distance RNA interactions. Virology. 2008;373(1):1–13.CrossRefGoogle Scholar

Copyright information

© Springer Nature Switzerland AG 2018

Authors and Affiliations

  • Patrick L. Iversen
    • 1
  1. 1.LS PharmaOregon State UniversityGrand JctUSA

Personalised recommendations